| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.078 | 0.08 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.08 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.051 | 0.09 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.047 | 0.1 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |